Brain damage hides behind a perfect score. On The Peter Attia Drive, neurologist Gayatri Devi argues that high-functioning professionals, like lawyers, can ace the Mini-Mental State Exam while their spatial reasoning collapses to the 10th percentile. Their cognitive reserve compensates for local failures, masking the disease until a breaking point. Devi’s diagnostic protocol involves hours-long testing to uncover these subtle gaps.
She views Alzheimer’s as a spectrum where memory, language, and visual-spatial domains decay at different velocities. By the time a high achiever fails a basic test, the window for early intervention has closed. Amyloid prevalence rises sharply with age - 25% in people in their 70s, 44% by age 90 - often without symptoms. Devi warns against diagnosing Alzheimer’s solely on amyloid biomarkers.
The new anti-amyloid drugs Lecanamab and Donanemab carry a significant risk of ARIA - brain swelling or bleeding. The risk is highest for patients with two copies of the APOE4 gene, which increases Alzheimer’s risk by 60%, a risk level Devi compares to BRCA for breast cancer. In clinical trials, ARIA rates reached 40% in some groups. Devi argues the FDA-approved titration schedules are too aggressive for these vulnerable patients.
“It matters little if the amyloid is gone in 18 months or 24 months if the patient suffers a massive bleed.”
- Gayatri Devi, The Peter Attia Drive
She implements a personalized, ultra-slow titration protocol in her practice, reducing ARIA incidence to roughly 4%. Insurance companies frequently refuse to reimburse these safer, off-label schedules, forcing high-risk patients to choose between standard dosing or paying out of pocket. Devi prioritizes safety over speed of plaque clearance. The drugs show small benefits - improving CDR-SB scores by 0.3-0.4 points out of 18 - but early intervention before significant tau pathology yields greater benefit.
Neuroinflammation is a new frontier. Devi points to evidence linking viruses like shingles and herpes simplex to cognitive decline. These pathogens may trigger the inflammatory cascade that leads to amyloid deposition. Aggressive vaccination and antiviral suppression are now core pillars of her preventative strategy.
A massive diagnostic gap exists in women’s health. Menopause-related cognitive impairment often looks identical to early-stage Alzheimer’s. Devi has seen patients misdiagnosed with dementia who were simply suffering from the loss of estrogen receptors in the hippocampus. Hormone replacement therapy can often stabilize or reverse these ‘pseudo-dementia’ symptoms. The ‘lost generation’ of women denied HRT after the 2002 Women’s Health Initiative is now reaching the age where this lack of neuroprotection manifests as cognitive failure.
